MARKET IS OPEN
Loading latest tickers...
Market Indices
S&P 500
$7,722.72
+0.73%
NASDAQ 100
$30,807.93
+1.00%
DOW JONES
$51,177.00
+0.49%
NASDAQ Composite
$27,190.86
+1.19%
RUSSELL 2000
$2,815.20
+0.90%
CBOE VIX
$15.31
-6.59%
Sector Heatmap
Technology+1.01%
Financials+0.06%
Healthcare-0.01%
Consumer Cycl+1.13%
Consumer Staples+0.25%
Energy+0.40%
Industrials+0.78%
Materials+0.66%
Real Estate+0.32%
Utilities+0.38%
Comm Services+0.35%
HROW — Harrow, Inc. Common Stock
NasdaqHarrow, Inc. Common Stock
$30.48
-0.13(-0.42%)
- O
- 30.83
- H
- 30.97
- L
- 30.15
- V
- 566.1K
⏱️ End-of-day dataAs of Oct 2, 2026
HROW — Latest News & Headlines
9 StoriesHROW News | HARROW INC (NASDAQ:HROW) - ChartMill
HROW News | HARROW INC (NASDAQ:HROW) ChartMill
TYRVAYA is the only FDA-approved nasal spray for dry eye. Harrow acquired its rights outside Japan. - Stock Titan
TYRVAYA is the only FDA-approved nasal spray for dry eye. Harrow acquired its rights outside Japan. Stock Titan
(HROW) Risk Channels and Responsive Allocation - Stock Traders Daily
(HROW) Risk Channels and Responsive Allocation Stock Traders Daily
Insider Confidence In These Growth Stocks For September 2026 - Simply Wall Street
Insider Confidence In These Growth Stocks For September 2026 Simply Wall Street
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach - TradingView
Biotech ETF XBI Hits an Interest Rate Wall as 40+ Catalysts Approach TradingView
Harrow Health stock falls 1.55 percent despite Q2 growth - AD HOC NEWS
Harrow Health stock falls 1.55 percent despite Q2 growth AD HOC NEWS
Harrow, Inc. stock gains as market cap nears USD 1.2 billion - AD HOC NEWS
Harrow, Inc. stock gains as market cap nears USD 1.2 billion AD HOC NEWS
Harrow stock highlights 15 ophthalmic studies at AAO - AD HOC NEWS
Harrow stock highlights 15 ophthalmic studies at AAO AD HOC NEWS
Harrow Closes TYRVAYA Acquisition, Expanding Dry Eye Portfolio - TipRanks
Harrow Closes TYRVAYA Acquisition, Expanding Dry Eye Portfolio TipRanks